Results 201 to 210 of about 1,526,327 (294)

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Community preferences for 'mental health insurance coverage in Tehran using a discrete choice experiment. [PDF]

open access: yesCost Eff Resour Alloc
Talebianpour H   +4 more
europepmc   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Disease Burden and Disparities of Care for Kidney Health in the Asian Pacific Region: Summary Report From the Diversity and Equity Committee of APSN. [PDF]

open access: yesNephrology (Carlton)
Wu IW   +15 more
europepmc   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

open access: yes
Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy